drugset / Trial / NCT02989727

Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine

NCT02989727

Phase 4 Completed 150 enrolled University of Saskatchewan GlaxoSmithKline · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if patients with melancholic bipolar II depression are more responsive to lamotrigine than patients with non-melancholic bipolar II depression. To do this, the investigators will re-analyze a previous clinical trial that evaluated lamotrigine as a treatment for bipolar II depression (GSK-SCA100223; NCT00274677).

Timeline

Start
2003-11
Primary completion
2005-08
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lamotrigine Small molecule 200 mg